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Abstract
Background: Streptococcus pneumoniae is the most significant bacterial cause of community-acquired pneumonia
among children under five years worldwide. Updated resistance information of S. pneumoniae among children is
essential to adjust the recommendations for empirical treatment of community-acquired pneumonia, which will
have immense implications for local and global health. This study investigated the prevalence of antibiotic
resistance in isolated strains of S. pneumoniae and relationship with antibiotic use and demographic factors of
children under five in rural Vietnam in 2007.
Methods: In Bavi district, 847 children 6 to 60 months were selected from 847 households. The main child-
caregivers in the households were interviewed weekly using structured questionnaires to collect information of
daily illness symptoms and drug use for the selected child over a four-week period (from March through June
2007). In the 3
rd week, the children were invited for a clinical examination and to collect nasopharyngeal samples
for S. pneumoniae identification. Etest and disk diffusion were used to test antibiotic susceptibility.
Results: Of 818 participating children, 258 (32%) had ongoing respiratory infections, 421 (52%) carried S.
pneumoniae, and 477 (58%) had used antibiotics within the previous three weeks. Of the 421 isolates, 95% were
resistant to at least one antibiotic (401/421). Resistance to co-trimoxazole, tetracycline, phenoxymethylpenicillin,
erythromycin and ciprofloxacin was 78%, 75%, 75%, 70% and 28%, respectively. Low resistance was noted for
amoxicillin (4%), benzylpenicillin (4%), and cefotaxime (2%). The intermediate resistance to amoxicillin was 32%.
Multidrug-resistance was seen in 60%. The most common pattern was co-resistance to co-trimoxazole, tetracycline
and erythromycin. The proportion of children carrying resistant bacteria was higher among the children who had
used antibiotics in the previous three weeks.
Conclusions: Resistance to commonly used antibiotics and multidrug-resistance of S. pneumoniae in the area is
remarkably high. High-dose amoxicillin is the only investigated oral antibiotic that can possibly be used for
treatment of community-acquired pneumococcal infections. Strategies to promote appropriate prescribing and
dispensing of effective antibiotics should be immediately implemented for the benefit of local and global health.
Background
Streptococcus pneumoniae is the most significant bacter-
ial cause of community-acquired pneumonia among
children under five years worldwide [1]. S. pneumoniae
often colonizes the nasopharynx of healthy children and
can then, in specific situations, spread to the lungs,
paranasal tissues and cause mucosal infections, such as
pneumonia, or invade the bloodstream and cause
meningitis [2]. The infections caused by this pathogen
are among those least likely to be resolved without
effective antibiotic treatment. However, since 1980s, a
dramatic increase in antibiotic resistance among
S. pneumoniae has been observed in many parts of the
world [3-7]. Treatment failure associated with antibio-
tic-resistant pneumococci has been reported for patients
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probably the main factor driving the emergence of resis-
tance [9].
As in many other countries, a high prevalence of
S. pneumoniae resistant to common antibiotics has been
seen in studies in Vietnam [10,11]. A study conducted
in Bavi district in 1999 showed that 90% of 106 S. pneu-
moniae isolates in 200 children were resistant to at least
one antibiotic, 88% to tetracycline, 32% to trimetho-
prim/sulphonamide and 25% to chloramphenicol [10].
Updated resistance information, especially the resistance
of S. pneumoniae among children, is essential to adjust
the recommendations for empirical treatment of com-
munity-acquired pneumonia, which will have immense
implications for local and global health.
This study is part of a larger project conducted among
the population of a rural area in northern Vietnam
where data on health care providers and consumers’
knowledge as well as their use of antibiotics has been
obtained [12,13]. The aim of this paper is to estimate
t h ep r e v a l e n c eo fS. pneumoniae carriage, to assess its
antibiotic susceptibility, and to investigate possible asso-
ciations to antibiotic use, demographic factors of chil-
dren aged 6 to 60 months and households’ economic
status.
Methods
Study area
The study setting was Bavi district, 60 km west of
Hanoi, the capital of Vietnam. The district is divided
into lowland, highland and mountains. The population
is approximately 262,000 persons, of whom 8% are chil-
dren under five years of age. The basic public health
care system includes a district hospital with 150 beds, 3
regional polyclinics and 32 commune health stations.
An Epidemiological Field Laboratory (Filabavi) was
established in 1998 [14]. Baseline and re-census surveys
have been done every second year. Regular follow-up of
vital events is conducted every three months. The sur-
veillance database includes 69 clusters with about
51,000 inhabitants in 12,000 households. A cluster was
defined as an administrative unit, usually a village. On
average, there are about 600-700 inhabitants in each
cluster.
Subject and sample size
A sample of 847 children born from June 2002 to Octo-
ber 2006 was obtained from 847 households with at
least one child eligible for the study. The sample size
calculation was based on the assumption that antibiotic
use in children under five in the community during one
month was 70% [10], the expected drop out 30% and
the design effect 2.0 due to clustering. Children older
than 6 months were included to facilitate taking
nasopharyngeal samples. All the households in the lar-
gest clusters in each of three geographical areas were
selected to give about 280 households in each area.
Some clusters were excluded due to uneven economical
distribution in quintiles. In each household, one child
aged 6-60 months was randomly selected (if more than
one such child was present). Participants’ characteristics,
date of birth, sex, residential areas, parents’ education,
and households’ assets, expenditure, and income were
extracted from FilaBavi’s re-census survey 2007.
Drug use survey and identification of S. pneumoniae
carrier
The main child-caregivers in the households were inter-
viewed weekly using structured questionnaires to collect
information of daily illness symptoms and drug use for
the selected child over a four-week period (from March
through June 2007). The caregivers were also requested
to fill a form regarding daily drug use for their child.
When available, the drug package or prescription was
examined by the interviewers. Drugs use for the partici-
pating children were classified according to the Anato-
mical Therapeutic Chemical (ATC) classification system
[15], with the help of VN-pharmacy software [16]. This
study includes antibiotics that are classified as antibac-
terials for systemic use and aggregated at the level of
the active ingredient (level 5 of the ATC class J01) [15].
On the third Saturday of the survey period, the chil-
dren were invited to the health commune station for a
clinical examination by paediatricians from district or
central hospitals. Trained microbiologists collected naso-
pharyngeal samples. The swabs were immediately placed
in a transport tube with charcoal transport medium.
Specimens were transported to Clinical Laboratories of
National Institute of Infectious and Tropical Diseases,
Hanoi, within 12 hours after sampling.
S. pneumoniae was isolated and identified using stan-
dard laboratory procedures [2, 1 7 ] .B r i e f l y ,p r e s u m p t i v e
S. pneumoniae isolates were picked based on typical col-
ony morphology, a-hemolysis, and Gram stain morphol-
ogy. Identification was confirmed by optochin sensitivity
with an inhibition zone diameter of ≥ 14 mm. A single
colony of each target bacterium was selected and sub-
cultured for purity check and further diagnostic mea-
sures of S. pneumoniae.
Antibacterial susceptibility testing
For all isolates, minimum inhibitory concentrations
(MICs) were determined for benzylpenicilin and cefotax-
ime using Etest (AB bioMéri e u x ,S o l n a ,S w e d e n ,f o r -
merly AB BIODISK). Inhibitory zone diameters were
estimated for erythromycin, co-trimoxazole, tetracycline,
and ciprofloxacin using disk diffusion (BIO-RAD
Laboratories, Marnes-la-Coquette, France). The tested
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treatment of pneumonia in Vietnam or recommended
for testing by the Clinical and Laboratory Standard
Institute (CLSI) [18]. Susceptibility testing was done
according to the performance standards of CLSI [18]
and manufacturers’ instructions. S. pneumoniae ATCC
49619 were included as a control strain.
Interpretative non-meningitis breakpoints were based
on the CLSI standards [18]. The inhibitory zone dia-
meters for isolates to be considered resistant were: tetra-
cycline ≤ 18 mm, co-trimoxazole ≤ 15 mm, erythromycin
≤ 15 mm. For ciprofloxacin, the criteria were: resistant
≤ 15 mm, susceptible ≥ 30 mm [19]. MICs values for
cefotaxime in the Etest were: resistant ≥ 4 mg/l, suscepti-
ble ≤ 1.0 mg/l.
According to CLSI guidelines, the isolates with MICs
≤ 2.0 mg/l for benzylpenicillin were considered as sus-
ceptible at doses of at least 2 million units every four
hours [18]. However, the possibility to administer the
doses required by CLSI is commonly not feasible in pri-
mary health care. In order to translate in vitro resistance
for benzylpenicillin to feasible treatment recommended
for patients with pneumococcal pneumonia, we modified
the current CLSI breakpoints using the European Com-
mittee on Antimicrobial Susceptibility testing (EUCAST)
categorization as: susceptible MICs ≤ 0.5 mg/l, inter-
mediate 1.0 mg/l≤ MICs ≤ 4.0 mg/l, resistant MICs ≥
8.0 mg/l [18,20]. The pneumococcal infections caused
by intermediate isolates may be appropriately treated
with a high dose of antibiotics [18,20].
We defined the isolates as susceptible to amoxicillin
and ampicillin using the same breakpoints as for benzyl-
penicillin [18]. Resistance to phenoxymethylpenicillin
was derived from benzylpenicillin MICs > 0.06 mg/l
[20]. Multidrug resistance was defined as isolates resis-
tant to at least three of six tested antibiotics, i.e benzyl-
penicilin, cefotaxime, erythromycin, co-trimoxazole,
tetracycline, and ciprofloxacin. Benzylpenicillin, ampicil-
lin, amoxicillin were grouped together as a single class.
We did not include phenoxylmethylpenicillin in the
multidrug-resistant analysis since its susceptibility was
derived from benzylpenicillin MIC.
Statistical analysis
Percentages of pathogen carriers and antibiotic-resis-
tance of S. pneumoniae with 95% confidence interval
(95% CI) were calculated to describe the nasopharyngeal
carriage of bacteria among children and resistance
among identified bacterium.
A wealth index defined as a combination of the infor-
mation on household income, expenditure and assets
was used to define the households’ economic status
[21]. The analysis based on this variable was initially
done using quintiles. These were then dichotomized
into two levels: those identified as living below average
conditions and those living at average or above
conditions.
Multiple regression models were used to examine the
statistical associations between antibiotic resistance and
the independent variables: sex (male vs. female), age
(24-60 months vs.6 - 2 3m o n t h s ) ,h o u s e h o l d ’se c o n o m i c -
status (average or above vs. below average), region
(highland, mountains vs. lowland), present ARI symp-
toms including any signs of respiratory infections at the
time of the nasopharynx sampling (yes vs. no), and anti-
biotics use within the three weeks preceding the sample
collection (yes vs. no).
Ethical considerations
The ethical review board of Hanoi Medical University
approved this study (No 28/HMURB, 2006). Verbal con-
sent of all parents was sought after explanation of the
purpose of the study. Confidentiality was assured and
participants were informed of their right to withdraw at
any time without any explanation. Children having a
condition in need of medical treatment were treated and
counselled by paediatricians from district or central
hospitals.
Results
Study population and S. pneumoniae carriage
For the 847 selected children, 823 (97%) caregivers gave
consent to participate in the drug use survey. Of these,
818 (99%) also consented for their child to participate in
the clinical examination and collection of nasopharyn-
geal samples. The characteristics and current health
situation of the children is presented in Table 1.
In the clinical examination, ARI symptoms were
reported in 258 children (32%). The most common
symptoms were mild ARIs such as cough, sore throat,
stuffy nose, or runny nose. Seven children had fever > 38°
C. Only one child was diagnosed as having pneumonia.
Children aged 6-23 months were more likely to present
ARI symptoms than children aged 24-60 months (34% vs.
29%). There were no significant differences regarding the
presence of ARI symptoms between geographical areas
or households’ economic conditions. Non-ARI symptoms
such as digestive disorder, skin rash, toothache, phymosis
were reported for 20% of the children.
Use of antibiotics during the three weeks preceding
the nasopharyngeal collection was reported for 58% of
t h ec h i l d r e n .T h ea v e r a g ea n t i b i o t i cc o u r s ew a s3 . 5 4
days (SD: 2.7 days), median 3.0 days indicating that 42%
used antibiotics in short courses (one or two days) and
a few reported a long treatment time. Penicillins with
extended-spectrum (ATC code: J01CA) such as ampicil-
lin, amoxicillin were most commonly used (49%), fol-
lowed by cephalosporins (J01D) 27%, sulphonamids and
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antibiotics including tetracyclines (J01A) and aminogly-
cosids (J01G) 3%. Most of the antibiotic courses were
used when nothing more than symptoms of mild ARIs
were presented. Children living in the mountainous area
more often used co-trimoxazole and those in the high-
land area more often used amoxicillin than other areas.
S. pneumoniae was isolated from 421 (52%) of the chil-
dren. Children aged 6-23 months were more likely to
carry S. pneumoniae than those aged 24-60 months
(Table 1). Moreover, children who had ARI symptoms
were more likely to carry the bacterium. There was no sig-
nificant difference in carrier prevalence related to prior
use of antibiotics or household’s economic condition.
S. pneumoniae antibiotic susceptibility
Table 2 shows the in-vitro activity of nine antibiotics
against 421 isolates of S. pneumoniae.N i n e t y - f i v ep e r -
cent of isolates (401/421) were resistant to at least one
of investigated antibiotics. A high level of resistance
was found to co-trimoxazole, tetracycline, phenoxy-
methylpenicillin and erythromycin (70-78%). Low resis-
tance was noted for benzylpenicillin (or amoxicillin and
ampicillin) (4%) and cefotaxime (2%). However, the
intermediate resistance to benzylpenicillin (or amoxicil-
lin and ampicillin) was 32%. More than one-quarter of
the S. pneumoniae isolates demonstrated resistance to
ciprofloxacin. Only one isolate was susceptible to all
antibiotics.
The distribution of benzylpenicillin and cefotaxime
MICs in the Etest is shown in Figure 1. The MIC of
benzylpenicillin at which 90% of isolates was inhibited
(MIC90) was 1.5 mg/l, while cefotaxime MIC90 was 0.75
mg/l. Moreover, we found 12 and 7 isolates for which
benzylpenicillin and cefotaxime MICs were higher than
32 mg/l (Figure 1.a, b). Almost all of those isolates were
resistant to co-trimoxazole, tetracycline, erythromycin,
and intermediate resistant to ciprofloxacin. In the disk
diffusion tests, 200/421 and 250/421 strains showed no
inhibitory zone (6 mm inhibitory-zone diameter) to co-
trimoxazole and erythomycin, i.e. these antibiotics had
no effect on most of the isolates (Figure 2.b, c).
Table 3 shows the relation between sex, age, economic
status, geographic condition, previous antibiotic use and
the prevalence of antibiotic resistance. Children living in
the mountainous area were more likely to carry erythro-
mycin and cotrimoxazol-resistant isolates than those in
other areas. The proportion of children carrying resis-
tant bacteria was higher among the children who had
used antibiotics within the three weeks prior to the
study for all antibiotics investigated. Prior treatment of
co-trimoxazole gave a higher risk of cotrimoxazol resis-
tance of the isolates.
Multidrug resistance among S. pneumoniae isolates
Most resistant isolates were multidrug resistant (252/
401), and they accounted for 60% of all isolates. Isolates
that were resistant to three classes of antibiotics were
Table 1 Characteristics of 818 community children aged 6-60 months and estimated prevalence of S. pneumoniae
nasopharyngeal carriage.
Characteristics Absolute number with percentage in bracket
Participating children
(% among total)
S. pneumoniae carrier
(% within group)
Sex Female 373 (46) 187 (50)
Male 445 (54) 234 (53)
Age 6-23 months 367 (45) 203 (55)*
24-60 months 451 (55) 218 (48)*
Region Lowland 268 (32) 145 (54)
Highland 275 (34) 146 (53)
Mountains 275 (34) 130 (47)
Households’ economic status Under average 358 (44) 196 (55)
Average or upper 460 (56) 225 (49)
ARI symptoms at the sampling time No presence 560 (68) 265 (47)*
Presence 258 (32) 156 (61)*
Other observation
§ No presence 650 (80) 340 (52)
Presence 168 (20) 81 (48)
Previous antibiotic use within 3 weeks No 341 (42) 183 (54)
Yes 477 (58) 238 (50)
Total 818 (100) 421 (52)
* Significant different between groups using c
2 test (p < 0.05).
§ Other observations: Non-ARI symptoms such as digestive disorder, skin rash, toothache, phymosis.
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14% (58/421). Co-resistance to five antibiotics was pre-
sented by 4 isolates.
Table 4 shows the pattern of co-resistance among the
S. pneumoniae isolates. The most common pattern was
co-resistance to co-trimoxazole, tetracycline, and ery-
thromycin (200/252). Penicillin-resistant pneumococcal
isolates are more likely to be concomitantly resistant to
cefotaxime, and co-trimoxazole than to other antibiotics.
Multi-resistance was not associated with sex, age, or
economic status but significantly higher in children liv-
ing in the mountainous area compared to other areas
(Table 3).
Discussion
This study shows that almost all of the S. pneumoniae
isolates from the children were resistant to at least one
of the investigated antibiotics. Most of the children had
Table 2 Susceptibility of 421 S. pneumoniae isolates to antibiotic agents
Antibiotic agents ATC code Absolute number and percentage in bracket
Resistant (R) Intermediate (I) Susceptible (S)
Tetracycline J01AA07 314 (75) 44 (10) 63 (15)
Benzylpenicillin J01CE01 17 (4) 136 (32) 268 (64)
Phenoxymethylpenicillin* J01CE02 315 (75) - 106 (25)
Ampicillin** J01CA01 17 (4) 136 (32) 268 (64)
Amoxicillin** J01CA04 17 (4) 136 (32) 268 (64)
Cefotaxime J01DD01 9 (2) 14 (3) 398 (95)
Co-trimoxazole J01EE01 329 (78) 47 (11) 45 (11)
Erythromycin J01FA01 294 (70) 52 (12) 75 (18)
Ciprofloxacin J01MA02 119 (28) 296 (70) 6 (2)
* Susceptibility to phenoxymethylpenicillin is derived from benzylpenicillin MICs according to EUCAST documents.
** Susceptibility to ampicillin and amoxicillin are derived from benzylpenicillin MICs according to CLSI documents.
Figure 1 Distribution of estimated minimum inhibitory concentration (MIC) by Etest. Figure 1 shows the distribution of estimated
minimum inhibitory concentration (MIC) for penicillin (a) and cefotaxime (b) against 421 S. pneumoniae isolates.
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diameter by disk diffusion for tetracycline (a), co-trimoxazole (b), erythoromycin (c) and ciprofloxacin (d) against 421 S. pneumoniae isolates.
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Characteristics
Total number of carrier in bracket
Percentage of resistant strains among total carriers within each category
TET
† PEN G
†
(AMX,
AMP)
PEN V
† CTX
† SXT
† ERY
† CIP
† MDR
†
Sex
- Female
R (187) 68* 5 72 3 78 67 25 56
- Male (234) 80* (**) 3 77 1 79 72 31 63
Age
- 6-23 months
R (217) 75 4 76 3 78 73 27 61
- 24-60 months (204) 74 2 74 2 78 67 29 59
Region
- Lowland
R (145) 77 2 78 0* 74* 68* 32 55*
- Highland (146) 72 6 77 5* 74* 64* 24 56*
- Mountains (130) 75 4 69 2* 88* (**) 78* 29 70* (**)
Economic status
- Under average
R (203) 79 5 76 3 80 72 31 61
- Average or upper (218) 71 3 74 1 76 68 26 59
Prior antibiotic use
-N o
R (183) 73 3 68* 0.5* 73* 67 26 56
- Yes (238) 76 5 80*(**) 3* 82*(**) 72 30 63
Total (421) 75 4 75 2 78 70 28 60
* p < 0.05: significant different between groups using c
2 test.
** Significant difference between group vs. reference using multiple logistic regression analysis.
R Reference groups in multiple logistic regression analysis
† TET: tetracycline, PEN G: benzylpenicillin, AMX: amoxicillin, AMP: ampicillin, PEN V: phenoxymethylpenicillin, CTX: cefotaxime, SXT: co-trimoxazole, ERY:
erythromycin, CIP: ciprofloxacin, MDR: multidrug-resistant.
Figure 3 Change of estimated susceptibility prevalence of S. pneumoniae isolates between 2007 and 1999.F i g u r e3c o m p a r e st h e
estimated susceptibility prevalence to five antibiotics between 421 S. pneumoniae isolates in 2007 and 106 isolates in 1999 in Bavi district.
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sample collection. There was a statistical association
between antibiotic use and resistance. All the oral anti-
biotics investigated showed very low level of susceptibil-
ity except for high-dose amoxicillin that can possibly be
used for treatment of pneumococcal infections.
S. pneumoniae c a r r i a g ep r e v a l e n c ee s t i m a t ew a s5 2 % ,
similar to the results of some other studies in Vietnam
[10,11], but higher than reported elsewhere [22,23]. The
carriage was lower in the older children, which is in
accordance with other studies [24]. Unlike previous
reports [25], however, the association between nasophar-
yngeal carriage of S. pneumoniae and prior antibacterial
use was not present and this might be explained by the
high levels of resistance discovered. A relationship
between pneumococcal nasopharyngeal carriage to the
spread of the pathogen and the development of pneu-
mococcal diseases has been reported [26]. Implementa-
tion of conjugate vaccine could protect against
pneumococcal carriage and reduce the risk of develop-
ing infection [27,28]. However, these vaccines are still
expensive and may not help to reduce nasopharyngeal
carriage in non-vaccine serotype carriage [27].
The resistance to all oral commonly used antibiotics
investigated among the 421 S. pneumoniae isolates was
markedly higher than previous research [3-6]. The resis-
tance prevalences were considerable higher than those
reported in 1999 in the same area, except for tetracy-
cline (Figure 3) [10]. A significant increase of drug-resis-
tant pneumococcal isolates from rural area was also
noted in Khanh Hoa province, Vietnam [29]. One of the
most serious findings is the high multidrug resistance
among the isolates (60%). This was distinctively higher
than reported from the Netherlands, Russia and Sweden,
however still lower than several other Asian countries
[30,31]. The finding is particularly worrying, as co-resis-
tance to co-trimoxazole-tetracycline-erythromycin is the
most common pattern. The high prevalence of multi-
resistant pathogens shows that the practice of combin-
ing drugs in empirical treatment in the case of resis-
t a n c em i g h tn o tb ee f f e c t i v ei nt h i sc o n t e x t .
Nevertheless, the national IMCI guidelines recommend
five days of antibiotic therapy (anyone of co-trimoxazole,
oral amoxicillin, and erythromycin) for treatment of
pneumonia among children 2 months up to 5 years in
the community [32]. This study shows that, co-trimoxa-
zole and erythromycin can be expected to be virtually
useless in this context and the recommendation of these
drugs should be seriously considered. The emergence of
S. pneumoniae strains showing “very high” resistance to
benzylpenicillin and cefotaxime has rarely been reported
internationally [33]. To address the characteristics of
such isolates requires further study. The phenomenon
of high resistance to commonly used antibiotics would
imply a challenge for empirical treatment of pneumo-
coccal infections in the area.
Which factors could have led to the very high level of
S. pneumoniae antibiotic resistance and multidrug-
resistance in this region? One important factor is prob-
ably the frequent and irrational use of antibiotics that
constitutes a constant selective pressure. In this study
area, many children frequently use antibiotics [10,34];
antibiotic use was also higher among children with pneu-
mococcal resistant strains. The higher level of co-trimox-
azole and multidrug resistance in the mountainous area
m a ym a i n l yb ed u et oh i g h e ru s eo fc o - t r i m o x a z o l ei n
this area and leading to differential selective pressure in
different areas. Some resistant clones of S. pneumoniae
spreading with different degrees of success may also be
r e s p o n s i b l ef o rt h eg e o g r a p h i c a ld i f f e r e n c eo fr e s i s t a n c e
[35]. The easy transmission of the pathogen between
individuals could facilitate the spread of multidrug resis-
tant strains through a small number of resistant mutants
[30,36]. Previous studies found two pandemic clones Tai-
wan 19F and Spanish 23F to be important among pneu-
mococcal isolates in Vietnam [3,11,28,29,37]. The global
Table 4 Pattern of co-resistance to tested antibiotics among 421 S. pneumoniae isolates
Individual antibiotic and combination Absolute number of co-resistance with percentage of total 421 isolates in bracket
CIP
† PEN G
† CTX
† CIP-PEN G CIP-
CTX
PEN G-CTX CIP- CTX - PEN G
119 (28) 17 (4) 9 (2) 1 (0.2)* 2 (0.5) 5 (1)* 0 (0)
SXT
† 329 (78) 86 (20) 17 (4)* 9 (2) 1 (0.2) 2 (0.5) 5 (1) 0 (0)
TET
† 314 (75) 99 (24)* 13 (3) 7 (2) 1 (0.2) 2 (0.5) 3 (1) 0 (0)
ERY
† 294 (70) 66 (16)* 15 (4) 6 (1) 1 (0.2) 0 (0) 4 (1) 0 (0)
SXT - TET 254 (60)* 73 (17) 13 (3) 7 (2) 1 (0.2) 2 (0.5) 3 (1) 0 (0)
SXT - ERY 248 (59)* 51 (12) 15 (4) 6 (1) 1 (0.2) 0 (0) 4 (1) 0 (0)
TET - ERY 241 (57)* 60 (14) 13 (3) 5 (1) 1 (0.2) 0 (0) 3 (1) 0 (0)
SXT-TET-ERY 200 (48) 45 (11) 13 (3) 5 (1) 1 (0.2) 0 (0) 3 (1) 0 (0)
*Significant different between resistant groups vs. non-resistant groups using c
2 test (p < 0.05).
† TET: tetracycline, PEN G: benzylpenicillin, CTX: cefotaxime, SXT: co-trimoxazole, ERY: erythromycin, CIP: ciprofloxacin.
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possibly partly contributes to the increase in resistance in
this region [37,38]. Further, the genetic determinants for
resistant clones usually exist in a stable form, so once
resistance is established, it is not easily lost [36].
Although the use of tetracycline in the region recently is
very low compared to three decades ago, the persistence
of high resistance to this antibiotic indicates the stability
of the resistant clones [34]. High resistance to ciprofloxa-
cin among the strains of children could be due to the
spread of already resistant strains from adults [3,39]. The
frequent inappropriate practices of prescribers and drug
sellers regarding antibiotic use for treatment of acute
respiratory infections may be one explanation for the
high level of antibiotic use and resistance in the area [13].
Other explanation might involve patients’ misperceptions
and self-medication with antibiotics [12].
What antibiotics can possibly be used for empirical
treatment of pneumococcal infections considering the
high levels of antibiotic resistance? Clinicians may find
it safe to choose susceptible antibiotics in empirical
practice. On the other hand, if the effective antibiotics
are more commonly used, this will promote the emer-
gence of even more multidrug-resistant bacteria. Cefo-
taxime has the highest susceptibility among the
investigated antibiotics. This drug is a broad-spectrum
antibiotic and if used widely and indiscriminately, resis-
tance to this antibiotic in S. pneumoniae m a yb e c o m ea
problem in the near future [28,40]. Hence, the still effec-
tive antibiotics need to be reserved for the severe cases
in tertiary hospitals and in selected cases with trouble-
some resistance patterns. Benzylpenicillin has a low level
of resistance (4%), but this antibiotic is administrated by
injections every 4-6 hours. Therefore, it is not feasible
to use benzylpenicillin as the first-line for treatment.
The use of narrow spectrum penicillins such as phenox-
ymethylpenicillin is higher among northern Europe
countries where there is also generally a low rate of
antibiotic resistance [9,41]. However, high resistance to
phenoxymethylpenicillin in this study (75%) may lead to
a poor clinical outcome if used as empirical treatment
[8]. Amoxicillin is thus the only oral antibiotic that can
possibly be used for treatment of pneumococcal pneu-
monia among children in the study area. Being low cost,
easily accessible and efficacious, amoxicillin has been
strongly recommended as the initial antibiotic for treat-
ment of non-severe pneumonia especially where co-tri-
moxazole resistance is common [42]. According to
pharmacokinetic-pharmacodynamic principles, the
appropriate dose of amoxicillin is the one that maxi-
mizes the time when the plasma concentration persists
above the MICs of the etiological agent (t > MIC) [43].
For that reason, the aim is to increase the t > MIC by
increasing the number of daily doses to achieve
bactericidal activity against isolates with MIC ≥ 2m g / l
[18,20,44]. To assure the therapeutic effect for at least
95% of pneumococcal infections in the context, the
recommended dose of amoxicillin at 25 mg/kg × 3
times daily thus appears to be too low [32,42,44]. The
guidance to increase the dose needs to be further
demonstrated by clinical research.
The study has several strengths. It is a community
study since the children were studied in their house-
holds and not in hospitals or clinics. The latter is a
common approach but the selection process will mean
that the studies only represent those seeking health care.
The results are internally valid for those clusters actually
investigated. The generalization of the result, the exter-
nal validity, must be based on theoretical propositions
suggesting that clusters or district are quite similar in
respects of the phenomenon under study, the antibiotic
resistance. Nothing indicates that similar rural areas
should be very different. The clusters selected were the
largest clusters for logistic reasons. As far as it can be
investigated, nothing suggests a tendency to higher car-
riage or resistance in the larger clusters. The participa-
tion percentage is high. The study had been carefully
piloted and field-tested. The training and supervising of
the interviewers and lab workers had been conducted
both in the field and in the laboratory to control the
quality of collected data. By using both CLSI and
EUCAST guidelines to define the interpretative break-
points for benzylpenicillin, the resistance data is consid-
ered to be more useful for developing countries’
conditions.
T h em a j o rl i m i t a t i o no ft h es t u d yw a st h a td u et ot h e
limited resources, we only performed Etest for benzylpe-
nicillin and cefotaxime. The susceptibility test for cipro-
floxacin is not recommended by CLSI, but the test for
S. pneumoniae is considered as an appropriate marker
for monitoring fluoroquiniolone resistance [19,20,45].
Conclusions
Resistance to commonly used antibiotics and multidrug-
resistance of S. pneumoniae in the investigated area are
remarkably high. Of all oral antibiotics investigated, only
high-dose amoxicillin can possibly be used as the first-
line of choice for empirical treatment of pneumococcal
infections among children in the area. The antibiotic
use within the three weeks prior to the study was higher
among the children with resistant pneumococci. In
patients who truly warrant therapy, consideration must
be given to use the most effective antibiotic class to
achieve a favourable therapeutic outcome and prevent
the emergence of antibiotic resistance. Strategies to pro-
mote appropriate prescribing and dispensing of effective
antibiotics should be immediately implemented for the
benefit of local and global health.
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